72 related articles for article (PubMed ID: 19748669)
1. In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia.
Schneider P; Costa O; Legrand E; Bigot D; Lecleire S; Grassi V; Vannier JP; Vasse M
Leuk Res; 2010 Jan; 34(1):24-31. PubMed ID: 19748669
[TBL] [Abstract][Full Text] [Related]
2. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor.
Scrideli CA; Cortez MA; Yunes JA; Queiróz RG; Valera ET; da Mata JF; Toledo SR; Pavoni-Ferreira P; Lee ML; Petrilli AS; Brandalise SR; Tone LG
Leuk Res; 2010 Jan; 34(1):32-7. PubMed ID: 19875168
[TBL] [Abstract][Full Text] [Related]
3. Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement.
Suminoe A; Matsuzaki A; Hattori H; Koga Y; Ishii E; Hara T
Leuk Res; 2007 Oct; 31(10):1437-40. PubMed ID: 17350093
[TBL] [Abstract][Full Text] [Related]
4. Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia.
Poyer F; Coquerel B; Pegahi R; Cazin L; Norris V; Vannier JP; Lamacz M
Leuk Res; 2009 Mar; 33(3):407-17. PubMed ID: 18829111
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
7. High nerve growth factor receptor (p75NTR) expression is a favourable prognostic factor in paediatric B cell precursor-acute lymphoblastic leukaemia.
Troeger A; Gudowius S; Escherich G; den Boer ML; Glouchkova L; Ackermann B; Meisel R; Laws HJ; Groeger M; Wessalowski R; Willers R; Harbott J; Pieters R; Goebel U; Janka-Schaub GE; Hanenberg H; Dilloo D
Br J Haematol; 2007 Nov; 139(3):450-7. PubMed ID: 17910636
[TBL] [Abstract][Full Text] [Related]
8. Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression.
Cascavilla N; Musto P; D'Arena G; Ladogana S; Matera R; Carotenuto M
Haematologica; 1997; 82(1):31-7. PubMed ID: 9107079
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous and cytokine-evoked production of matrix metalloproteinases by bone marrow and peripheral blood pre-B cells in childhood acute lymphoblastic leukaemia.
Pegahi R; Poyer F; Legrand E; Cazin L; Vannier JP; Lamacz M
Eur Cytokine Netw; 2005 Sep; 16(3):223-32. PubMed ID: 16266864
[TBL] [Abstract][Full Text] [Related]
10. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
11. Validation by RQ-PCR and flow cytometry of alpha-defensin1-3 (DEFA1-3) overexpression in relapsed and refractory acute lymphoblastic leukemia.
Te Kronnie G; Bicciato S; Franceschini L; Accordi B; Dellíorto MC; Rinaldi A; Pession A; Barisone E; Conter V; Locatelli F; Basso G
Oncol Rep; 2006 Feb; 15(2):341-6. PubMed ID: 16391852
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
13. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in childhood acute lymphoblastic leukemia in Japan. Japan Association of Childhood Leukemia Study.
Horibe K; Hara J; Yagi K; Tawa A; Komada Y; Oda M; Nishimura S; Ishikawa Y; Kudoh T; Ueda K
Int J Hematol; 2000 Jul; 72(1):61-8. PubMed ID: 10979211
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction.
Koomagi R; Zintl F; Sauerbrey A; Volm M
Clin Cancer Res; 2001 Nov; 7(11):3381-4. PubMed ID: 11705851
[TBL] [Abstract][Full Text] [Related]
17. Correlation of telomerase activity to apoptosis and survival in adult acute lymphoblastic leukemia: an Egyptian single-center study.
Asfour IA; Fayek MH; El-Kourashy SA; Youssef SR; El-Gohary GM; Mohamed OF
Ann Hematol; 2008 Mar; 87(3):213-21. PubMed ID: 18175116
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
19. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
Wu S; Korte A; Gessner R; Henze G; Seeger K
Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
[TBL] [Abstract][Full Text] [Related]
20. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
Klein G; Vellenga E; Fraaije MW; Kamps WA; de Bont ES
Crit Rev Oncol Hematol; 2004 May; 50(2):87-100. PubMed ID: 15157658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
